Loading...

ALT ALTIMMUNE INC Expansion Plans 8-K Filing

LTMM

LT

ALTIMMUNE INC

(ALT)

2025 8-K

Financial Results Report

Annual Meeting Announcement

Funding Announcement

Positive Trial Results

Management Transition

New Equity Offering

Loan Agreement Update

Management Change

Annual Meeting Results

Clinical Trials

Debt-Equity Swaps

New Indications

Management Change

Board Appointments

Financial Results

CFO Appointment

Annual Meeting Results

Earnings Reports

Appointment of Acting CFO

Earnings Reports

Financial Results and Obesi...

Obesity trial results

Earnings Reports

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Appointment of Director

Earnings Reports

External Links:

On December 19, 2025, Altimmune, Inc. announced positive results from the IMPACT Phase 2b trial of pemvidutide, showing significant improvements in liver fibrosis markers compared to placebo, with weight loss of 4.5% and 7.5% for doses of 1.2 mg and 1.8 mg, respectively.

AI Assistant

ALTIMMUNE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.